Omnicell (OMCL)
(Delayed Data from NSDQ)
$42.39 USD
+0.88 (2.12%)
Updated Oct 4, 2024 03:59 PM ET
After-Market: $42.36 -0.03 (-0.07%) 7:58 PM ET
1-Strong Buy of 5 1
B Value B Growth C Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$42.39 USD
+0.88 (2.12%)
Updated Oct 4, 2024 03:59 PM ET
After-Market: $42.36 -0.03 (-0.07%) 7:58 PM ET
1-Strong Buy of 5 1
B Value B Growth C Momentum B VGM
Zacks News
Should iShares S&P SmallCap 600 Growth ETF (IJT) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for IJT
3 Reasons Why Growth Investors Shouldn't Overlook Omnicell (OMCL)
by Zacks Equity Research
Omnicell (OMCL) could produce exceptional returns because of its solid growth attributes.
CERN vs. OMCL: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
CERN vs. OMCL: Which Stock Is the Better Value Option?
Should SPDR S&P 600 Small Cap Growth ETF (SLYG) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for SLYG
Should Vanguard S&P SmallCap 600 Growth ETF (VIOG) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for VIOG
Is GlaxoSmithKline (GSK) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how GlaxoSmithKline (GSK) and Omnicell (OMCL) have performed compared to their sector so far this year.
Should SPDR Portfolio S&P 600 Small Cap ETF (SPSM) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for SPSM
Omnicell (OMCL) is an Incredible Growth Stock: 3 Reasons Why
by Zacks Equity Research
Omnicell (OMCL) could produce exceptional returns because of its solid growth attributes.
NEOGEN (NEOG) Inks Deal to Boost Global Genomics Business
by Zacks Equity Research
NEOGEN's (NEOG) latest acquisition of Genetic Veterinary Sciences, Inc. will bolster the global genomics business.
NextGen's (NXGN) Integrated Platform Gets Adopted by Monmouth
by Zacks Equity Research
NextGen's (NXGN) comprehensive solution suite was adopted by Monmouth to better cater to patients' medical and dental needs.
CERN vs. OMCL: Which Stock Is the Better Value Option?
by Zacks Equity Research
CERN vs. OMCL: Which Stock Is the Better Value Option?
Omnicell (OMCL) Down 1% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Omnicell (OMCL) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
NEOGEN (NEOG) Strengthens Global Foothold With Delf Buyout
by Zacks Equity Research
NEOGEN (NEOG) management believes that Delf's 40 years of experience in the UK dairy hygiene market will help it strengthen its foothold in this region's dairy chemicals market.
Walgreens Boots (WBA) Faces Margin Pressure, Solvency Issue
by Zacks Equity Research
Of late, increased reimbursement pressure and generic drug cost inflation have been hampering Walgreens Boots' (WBA) margin significantly.
Medtronic (MDT) Gets Health Canada License for GI Genius Module
by Zacks Equity Research
Medtronic Canada ULC, a subsidiary of Medtronic (MDT), receives Health Canada license for the GI Genius module that aids in colorectal cancer screening.
Here's Why You Should Invest In Bruker (BRKR) Stock for Now
by Zacks Equity Research
Investors are optimistic about Bruker's (BRKR) better-than-expected results and strong segmental performance.
QIAGEN (QGEN), DiaSorin to Broaden Access to Latent TB Testing
by Zacks Equity Research
QIAGEN (QGEN) and DiaSorin gained FDA approval for their jointly-created LIAISON QuantiFERON-TB Gold Plus assay for use on DiaSorin's automated LIAISON XS platform.
Here's Why You Should Hold on to Globus Medical (GMED) for Now
by Zacks Equity Research
Investors are optimistic about Globus Medical's (GMED) better-than-expected earnings and robust ExcelsiusGPS performance.
Here's Why You Should Retain ResMed (RMD) Stock for Now
by Zacks Equity Research
Investors are optimistic about ResMed (RMD) given its better-than-expected results and robust SaaS business performance in the fiscal first quarter.
Is GlaxoSmithKline (GSK) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how GlaxoSmithKline (GSK) and Omnicell (OMCL) have performed compared to their sector so far this year.
Smith+Nephew (SNN) Introduces Real Intelligence & CORI System
by Zacks Equity Research
Smith+Nephew (SNN) debuts new brand of enabling technology solutions as well as its next-generation handheld robotics platform in Canada.
Here's Why You Should Hold on to Integra (IART) Stock for Now
by Zacks Equity Research
Investors are optimistic about Integra (IART) given its better-than-expected results and robust performance of the CSS arm in the third quarter.
Allscripts' (MDRX) Services Leveraged by Next Level Urgent Care
by Zacks Equity Research
Allscripts' (MDRX) Touchworks platform and Microsoft Azure hosting & services will be implemented across all Next Level Urgent Care's sites in Houston.
Here's Why You Should Hold on to Syneos Health (SYNH) for Now
by Zacks Equity Research
Investors about optimistic about Syneos Health (SYNH) given its better-than-expected results as well as strong segmental performance during the third quarter.
3 Reasons Growth Investors Will Love Omnicell (OMCL)
by Zacks Equity Research
Omnicell (OMCL) could produce exceptional returns because of its solid growth attributes.